Scientist I/II, Translational Research
Ikena Oncology (NASDAQ: IKNA) is a clinical-stage, targeted oncology company that discovers and develops biomarker-driven therapies for cancer patients who need life-saving treatment, by understanding what drives their disease. Ikena is advancing five clinical, preclinical, and discovery programs and has a global strategic collaboration with Bristol Myers Squibb. Since inception, Ikena has raised over $300 million from leading life sciences investors and companies that include Atlas Venture, OrbiMed, BMS, Fidelity, Omega Funds, Surveyor Capital (a Citadel company), Invus, Farallon Capital Management, BVF Partners, Cowen Healthcare Investments, Logos Capital, and HealthCor Management. Ikena priced its IPO in March 2021 and trades on the NASDAQ (Ticker: IKNA).
The translational research group is looking for a talented and creative scientist who is passionate about oncology research that directly informs and shapes clinical trial designs. Areas of focus include patient selection strategy, sensitivity/resistance to agents targeting major oncogenic drivers and pathways, and rationale design of combination therapies. This individual will contribute and support multiple programs at late-stage discovery or development.
- Work effectively across functions to evaluate therapeutic impact of drug candidates in relevant disease models
- Explore novel patient-derived in vitro and in vivo models to test therapeutic hypotheses and patient selection strategies
- Develop disease-relevant models through cellular engineering
- Support identification of disease pathway related biomarkers to evaluate therapeutic impact of drug candidates in the clinic
- Support research to identify potential drug combinations
- Data analysis and presentation at group meetings
- Additional duties and responsibilities as required
- PhD with 0-2 years industry experience in biological sciences with a proven research accomplishments in oncology
- Non-PhD with strong relevant experience in biopharma industry will also be considered
- Strong background in using patient-derived or engineered models
- Experience in CRISPr and RNAi a plus
- Hands-on experience with various cell-based assay platforms to measure cell proliferation, apoptosis, protein phosphorylation, and gene expression
- Proficiency in basic molecular and cell biology techniques such as transfection, viral transduction, western blotting, qPCR, and immunostaining
- Ability to query public genomics databases to guide experimental design and hypothesis
- Good understanding of cancer biology and targeted oncology drug discovery
- Strong communication skill and a collaborative spirit
Personal attributes: team oriented, goal-driven, organized, highly collaborative, open-minded, data-driven, creative, persistent in the face of obstacles and uncertainty, flexible, self-aware of strengths and weaknesses, objective in the evaluation of data and strongly optimistic about overcoming challenges.